Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen dose optimization in children born small for gestational age
2015-001696-51Phase 3
- Sponsor
- Merck KGaA
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Small for gestational age (SGA) (2 arms), sponsored by Merck KGaA. Primary endpoint: Height velocity.
02
Drugs
somatropin
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on 2015-001696-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001696-51.